Daniel Carlat, MDDr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Throughout every issue of The Carlat Report, you, poor reader, have been subjected to citations of multiple research studies, and to terms such as "controlled," "open-label", "statistically significant." In this article, TCR dives head-first into research methodology, with the aim of helping you to become smarter consumers of statistical trickery.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.